PRVB实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2023 @ 04:00):

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases...

Stats
今日成交量	9.12M
平均成交量	2.84M
市值	2.38B
EPS	$0 ( 2024-03-27 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-16.43
ATR14	$0.594 (2.38%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-27	Sessa Capital (master), L.p.	Sell	15 567 497	Common Stock
2023-04-27	Wysenski Nancy	Sell	128 981	Option to Purchase Common Stock
2023-04-27	Wysenski Nancy	Sell	22 200	Option to Purchase Common Stock
2023-04-27	Wysenski Nancy	Sell	23 000	Option to Purchase Common Stock
2023-04-27	Wysenski Nancy	Sell	33 000	Option to Purchase Common Stock

INSIDER POWER
-62.73
Last 100 transactions
Buy: 11 373 023 \| Sell: 48 540 195

音量相关性

長: 0.34 (neutral)

短: 0.37 (neutral)

Signal:(80.187) Neutral

Provention Bio Inc 相关性

10 最正相关
KRBP	0.886
RICO	0.879
NETE	0.825
MMAC	0.812
LWAC	0.809

10 最负相关
SQBG	-0.875
TCAC	-0.873
TCACU	-0.869
RMRM	-0.85
SVAC	-0.82
TLGT	-0.819

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Provention Bio Inc 相关性 - 货币/商品

0.13
( neutral )

0.68
( moderate )

0.57
( weak )

0.45
( neutral )

-0.68
( moderate negative )

-0.14
( neutral )

Provention Bio Inc 财务报表

Annual	2022
营收:	$12.90M
毛利润:	$12.38M (96.03 %)
EPS:	$-1.520

FY	2022
营收:	$12.90M
毛利润:	$12.38M (96.03 %)
EPS:	$-1.520

FY	2021
营收:	$1.40M
毛利润:	$0.00 (0.00 %)
EPS:	$-1.810

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.880

Financial Reports:

No articles found.

Provention Bio Inc

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.